Use of zoledronate for treatment of a bone fragility disorder in horses

Katzman, Scott A.; Nieto, Jorge E.; Arens, Amanda M.; Macdonald, Melissa; Puchalski, Sarah M.; Galuppo, Larry D.; Snyder, Jack R.; Maher, Omar; Bell, Robin J.

doi:10.2460/javma.240.11.1323

Cited by 21 publications

(10 citation statements)

References 10 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, it has been concluded that CatK plays a role in the pathogenesis of equine osteoarthritis by degrading collagen type II (Vinardell et al, 2009). There are several reports on using antiresorptive drugs in equine bone resorption disorders (Coudry et al, 2007;Katzman et al, 2012). Moreover, some antiresorptives have been proposed for the treatment of dorsal metacarpal disease (bucked shins) and other bone resorption disorders in horses (Delguste et al, 2007;Kamm et al, 2008;Hussein & Bertone, 2015).…”

Section: Introductionmentioning

confidence: 99%

Repeated oral administration of a cathepsin K inhibitor significantly suppresses bone resorption in exercising horses with evidence of increased bone formation and maintained bone turnover

Hussein

Dulin

Smanik

et al. 2016

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Our investigations evaluated the effect of VEL-0230, a highly specific irreversible inhibitor of cathepsin K (CatK). The objectives of our study were to determine whether repeated dosing of a CatK inhibitor (CatKI) produced a desired inhibition of the bone resorption biomarker (CTX-1), and document the effect of repeated dosing on bone homeostasis, structure, and dynamics of bone resorption and formation in horses. Twelve young exercising horses were randomized in a prospective, controlled clinical trial and received 4 weekly doses of a CatKI or vehicle. Baseline and poststudy nuclear scintigraphy, blood sampling and analysis of plasma bone biomarkers (CTX-1 and osteocalcin), poststudy bone fluorescent labeling, and bone biopsy were performed. Bone specimens were further processed for microcomputed tomography and bone histomorphometry. Each dose of this CatKI transiently inhibited plasma CTX-1 (reflecting inhibition of bone collagen resorption) and increased bone plasma osteocalcin concentrations, with no detectable adverse effect on normal bone turnover in the face of exercise. Bone morphology, density, and formation rate were not different between control and treated group. Further investigation of CatK inhibition in abnormal bone turnover is required in animals with bone diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Repeated oral administration of a cathepsin K inhibitor significantly suppresses bone resorption in exercising horses with evidence of increased bone formation and maintained bone turnover

Hussein

Dulin

Smanik

et al. 2016

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…Electropherogram was normal in the current case. Since some horses affected with SAO respond to bisphosphonate therapy, treatment can be considered in other similar cases where neoplasia and infection have been ruled out (Katzman et al 2012).…”

Section: Discussionmentioning

confidence: 99%

Multifocal discrete osteolysis in a horse with silicate associated osteoporosis

Zavodovskaya

Eckert²,

Murphy

et al. 2018

Equine Veterinary Education

View full text Add to dashboard Cite

Summary Silicate associated osteoporosis (SAO) was diagnosed post‐mortem in an adult horse with the shortest documented exposure to cytotoxic silicates of 2 years. The horse was evaluated for a 6‐month history of progressive back tenderness and acute onset of lameness. The horse had a marked (4/5) (American Association of Equine Practitioners scale) left forelimb lameness, moderate (2/5) hindlimb ataxia and weakness, and cervical pain upon palpation. Physical examination did not reveal clinical skeletal deformities or respiratory compromise. Radiographs revealed widespread, discrete, sharply delineated, osteolytic lesions in the skull, vertebral column, ribs, scapulae and middle phalanx (P2) of the left forelimb and a diffuse bronchointerstitial lung pattern. The presumptive clinical diagnosis was widespread, metastatic osteolytic neoplasia. Due to the poor quality of life and grave prognosis, the horse was humanely euthanised. Post‐mortem examination revealed pulmonary silicosis in the lungs and hilar lymph nodes and osteolytic lesions with numerous, large osteoclasts and disorganised bone remodelling both consistent with SAO. SAO should be included as a differential diagnosis for horses with widespread, multifocal, discrete osteolysis and history of exposure to endemic regions with possible cytotoxic silicate inhalation. Exposure time of 2 years is potentially sufficient to develop SAO.

show abstract

“…The use of sedatives has little or no effect on the treatment of these animals. 83,84 As bisphosphonates reduce blood calcium levels, their use can result in severe hypocalcaemia. [75][76][77] Bisphosphonates Bisphosphonates are therapeutic agents, with strong affinity for bone, that markedly inhibit osteoclast activity.…”

Section: Fluphenazinementioning

confidence: 99%